China Pharma Holdings, Inc. (CPHI) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, China Pharma reported revenue of $4.1M, down 8.5% from $4.5M the year before. Net income was -$3.2M (a -76.9% net margin), or -$0.74 per diluted share. Gross margin was -3.2% and operating margin was -78.2%. Operating activities generated $148,261 of cash, leaving $10,676 of free cash flow. At fiscal year end, China Pharma held $31.0M in total assets against $8.3M in total liabilities, including $345,112 of cash and equivalents.
Open the full interactive China Pharma financials → Quarterly statements, key ratios, valuation history and price charts.
China Pharma Key Stats
| Share Price | $0.75 |
|---|---|
| Market Cap | $30.4M |
| Revenue YoY Growth | -8.5% |
| 52-Week Range | $0.52 – $8.10 |
| Shares Outstanding | 40.5 million (basic, 2026 Q2) |
China Pharma Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $10.9M | $9.6M | $8.1M | $7.0M | $4.5M | $4.1M |
| Gross Profit | $2.0M | $349,270 | -$493,916 | -$281,085 | -$2.0M | -$131,950 |
| Operating Income | -$2.6M | -$2.9M | -$3.5M | -$2.8M | -$4.6M | -$3.2M |
| Pre-Tax Income | -$2.9M | -$3.4M | -$4.0M | -$3.1M | -$4.7M | -$3.2M |
| Net Income | -$2.9M | -$3.4M | -$4.0M | -$3.1M | -$4.7M | -$3.2M |
| Diluted EPS | -$35.00 | -$35.00 | -$38.00 | -$9.10 | -$2.70 | -$0.74 |
China Pharma Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $756,217 | $1.2M | $983,536 | $948,340 |
| Net Income | -$651,482 | -$1.2M | -$1.1M | -$1.5M |
| Diluted EPS | -$0.17 | — | -$0.04 | -$0.04 |
China Pharma Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $957,653 | $4.9M | $2.0M | $1.4M | $600,000 | $345,112 |
| Current Assets | $5.3M | $9.1M | $6.0M | $6.0M | $3.3M | $2.3M |
| Total Assets | $21.1M | $22.6M | $17.8M | $16.5M | $14.9M | $31.0M |
| Current Liabilities | $11.4M | $10.5M | $12.7M | $6.8M | $5.0M | $7.4M |
| Total Long-Term Debt | $5.2M | $6.4M | $1.4M | $2.4M | $2.4M | — |
| Total Liabilities | $13.1M | $16.6M | $13.5M | $9.0M | $7.1M | $8.3M |
| Shareholders' Equity | $8.0M | $6.0M | $4.3M | $7.5M | $7.7M | $22.7M |
China Pharma Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$42,260 | -$249,838 | -$409,545 | -$699,686 | -$466,362 | $148,261 |
| Cash From Investing | -$867,307 | -$438,055 | -$401,964 | -$11,517 | -$291,718 | -$137,251 |
| Cash From Financing | $624,177 | $4.6M | -$1.8M | $73,145 | $27,353 | -$294,027 |
| Free Cash Flow | -$909,567 | -$687,893 | -$811,509 | — | -$538,411 | $10,676 |
Figures from China Pharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full China Pharma financials page for every line item.
China Pharma Company Profile
| Ticker | CPHI |
|---|---|
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Headquarters | Hainan Province, China |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001106644 |
Frequently Asked Questions
What was China Pharma's revenue in fiscal 2025?
China Pharma (CPHI) reported revenue of $4.1M for fiscal 2025.
What is China Pharma's annual revenue history?
China Pharma's annual revenue by fiscal year: 2020: $10.9M; 2021: $9.6M; 2022: $8.1M; 2023: $7.0M; 2024: $4.5M; 2025: $4.1M.
What was China Pharma's net income in fiscal 2025?
China Pharma reported net income of -$3.2M for fiscal 2025.
What was China Pharma's earnings per share (EPS) in fiscal 2025?
China Pharma's diluted EPS was -$0.74 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did China Pharma generate in fiscal 2025?
China Pharma generated $10,676 of free cash flow in fiscal 2025.
What was China Pharma's revenue last quarter?
In its most recent reported quarter (2026 Q2), China Pharma reported revenue of $948,340.
How many shares of China Pharma are outstanding?
China Pharma reported a weighted average of 40.5 million basic shares outstanding in 2026 Q2.
What is China Pharma's market cap?
Based on its latest closing price, China Pharma (CPHI) has a market capitalization of about $30.4M.
When does China Pharma's fiscal year end?
China Pharma's fiscal year end, as registered with the SEC, is December 31.
Where is China Pharma headquartered?
China Pharma lists its business address in Hainan Province, China in its SEC filings.